Original Article
Hyponatremia and Mortality among Patients on the Liver-Transplant Waiting List
N Engl J Med 2008; 359:1018-1026September 4, 2008
- Abstract
Background
Under the current liver-transplantation policy, donor organs are offered to patients with the highest risk of death.
Methods
Using data derived from all adult candidates for primary liver transplantation who were registered with the Organ Procurement and Transplantation Network in 2005 and 2006, we developed and validated a multivariable survival model to predict mortality at 90 days after registration. The predictor variable was the Model for End-Stage Liver Disease (MELD) score with and without the addition of the serum sodium concentration. The MELD score (on a scale of 6 to 40, with higher values indicating more severe disease) is calculated on the basis of the serum bilirubin and creatinine concentrations and the international normalized ratio for the prothrombin time.
Results
In 2005, there were 6769 registrants, including 1781 who underwent liver transplantation and 422 who died within 90 days after registration on the waiting list. Both the MELD score and the serum sodium concentration were significantly associated with mortality (hazard ratio for death, 1.21 per MELD point and 1.05 per 1-unit decrease in the serum sodium concentration for values between 125 and 140 mmol per liter; P<0.001 for both variables). Furthermore, a significant interaction was found between the MELD score and the serum sodium concentration, indicating that the effect of the serum sodium concentration was greater in patients with a low MELD score. When applied to the data from 2006, when 477 patients died within 3 months after registration on the waiting list, the combination of the MELD score and the serum sodium concentration was considerably higher than the MELD score alone in 32 patients who died (7%). Thus, assignment of priority according to the MELD score combined with the serum sodium concentration might have resulted in transplantation and prevented death.
Conclusions
This population-wide study shows that the MELD score and the serum sodium concentration are important predictors of survival among candidates for liver transplantation.
Media in This Article
Figure 1
Serum Sodium Concentration and the Relative Risk of Death after Adjustment for the MELD Score.Figure 2
Computation of the MELDNa Score on the Basis of the MELD Score and the Serum Sodium Concentration.Article Activity
- Article
The allocation of grafts for liver transplantation from deceased donors in the United States is based on medical urgency, which is estimated according to the Model for End-Stage Liver Disease (MELD) score. The MELD score is based on the results of three readily available, objective, and reproducible laboratory tests: the total serum bilirubin concentration, the international normalized ratio (INR) for the prothrombin time, and the serum creatinine concentration.1-4 In the United States, the MELD score has been used in determining priorities for organ allocation in liver transplantation since 2002.
In addition to the MELD score, the serum sodium concentration has been recognized as an important prognostic factor in patients with liver cirrhosis. For example, hyponatremia has been associated with the hepatorenal syndrome,5-9 ascites,6-10 and death from liver disease.5,8,10-14 The serum sodium concentration, like the components of the MELD score, is readily available, objective, and reproducible; this makes the serum sodium concentration a reasonable candidate for consideration in a model of liver allocation. Several studies have shown that among patients on the waiting list for liver transplantation, the serum sodium concentration is an important predictor of mortality, over and above the MELD score.15-18 Furthermore, it has been suggested that there may be an interaction between the MELD score and the serum sodium concentration in patients with a very high MELD score and that, among these patients, the addition of the serum sodium concentration may not have as important an effect on mortality as it does among patients with a low MELD score.16,18 The small size of the studies conducted to date has precluded adequate examination of the interaction between the MELD score and the serum sodium concentration. We used the Organ Procurement and Transplantation Network (OPTN) database to measure the effect of the MELD score, the serum sodium concentration, and the interaction between the two in predicting mortality among patients on a waiting list for liver transplantation.
Methods
Study Data
Data on all patients who were registered on the waiting list in the United States were obtained from the OPTN. These data were available from the Standard Transplant Analysis and Research file as of May 1, 2007. The predictor variables in this analysis consisted of the MELD score and the serum sodium concentration at the time of registration on the waiting list. The data file also included the outcome of waiting (i.e., transplantation, death, or withdrawal from the list for other reasons), which was used to define the outcome variable in the analysis — namely, death before transplantation and within 90 days after registration.
Since our data spanned 2 calendar years, we adopted a strategy to build a prediction model based on data from 2005 and to validate the model using the 2006 data. Since we planned to assign a prognostic score based on the MELD score and the serum sodium concentration to the current and future registrants on the waiting list, it was important that a model derived from one calendar year remain valid when it was applied to another year. Our target population was all adults with cirrhotic liver disease in the United States who were listed for a first liver transplantation. Therefore, among all registrants on the waiting list, we excluded those who were younger than 18 years of age, those with liver disease other than cirrhosis (e.g., acute liver failure or hepatocellular carcinoma), and those listed for repeat liver transplantation, as well as patients for whom complete laboratory data were not available within 5 days after they had been placed on the waiting list. In addition, since we were interested in the effects of hyponatremia, a small proportion of patients with hypernatremia (serum sodium concentration >150 mmol per liter) (24 of 6793 patients, or 0.4%) were excluded from the model development. However, patients with hypernatremia were included in the model validation in order to ensure that the new score could be applied globally. In candidates listed at more than one center concurrently, we identified the first date of registration on the waiting list, using a de-identified unique candidate code.
Statistical Analysis
The MELD score was calculated with the use of the standard formula, which adds multiples of the natural logarithm (ln) of the values for the INR, creatinine, and bilirubin as follows: 11.2 × ln (INR) + 9.57 × ln (creatinine, in milligrams per deciliter) + 3.78 × ln (bilirubin, in milligrams per deciliter) + 6.43 (an intercept), with a lower limit of 1 for all variables and with creatinine capped at 4; creatinine was set at 4 if the patient was receiving renal-replacement therapy. The MELD score (rounded to the nearest integer) ranges from 6 to 40, with higher values indicating more severe disease.
A multivariable Cox proportional-hazards analysis of the 2005 data was conducted to describe the relationships among the MELD score, the serum sodium concentration, and 3-month mortality. Patients who were withdrawn from the list and subsequently died were counted as having died. The remaining patients were excluded at the time of withdrawal from the waiting list, at the time of liver transplantation, or 90 days after registration on the waiting list. The Cox model assumed that excluded patients had the same risk as patients with the same covariate values who were not excluded. In other words, the model assumed that the selection of liver-transplant recipients among candidates with an identical MELD score was random. Thus, once the MELD score was taken into account in the model, the concern about potential biases (e.g., informative censoring) in the analysis because of exclusion at the time of liver transplantation was minimized.
Generalized additive models with smoothing splines were used to determine whether the serum sodium concentration had a nonlinear effect on the risk of death. The resulting smooth curves permit depiction of the relationship between the MELD score and mortality in several strata of sodium values. The interaction between the MELD score and the serum sodium concentration was formally evaluated by means of multivariable Cox regression analysis. To maintain consistency with the MELD score, the final model was constrained such that the new score (the MELD score combined with the serum sodium concentration) would have the lower and upper bounds of 6 and 40, respectively, for all strata of sodium values.
Once the prediction model had been finalized, it was applied to the 2006 data to examine whether the calibration and discrimination of the score based on the new model (the MELDNa score) were superior to those of the MELD score. Calibration describes how closely the predicted probabilities agree numerically with the actual outcomes.19 To test the calibration of the MELDNa score, for each decile of MELD scores for the 2005 data, we calculated the probability of death at 90 days and compared that probability with those predicted by the MELD score alone and the MELD score combined with the serum sodium concentration. We applied the Hosmer–Lemeshow statistic, as modified by D'Agostino and Nam,20 as a measure of calibration (see the Supplementary Appendix, available with the full text of this article at www.nejm.org). Discrimination refers to the ability of the model to correctly distinguish between two classes of outcomes such as death and survival.4,19 Statistical measures of discrimination, including the concordance statistics (C statistics) and integrated discrimination improvement (see the Supplementary Appendix), were computed.21,22 P values for the comparison of C statistics were calculated with the use of the bootstrap method. Finally, a reclassification table was created to estimate the magnitude of changes in ranking between the MELD score alone and the MELDNa score.21
Results
Characteristics of the Patients
A total of 14,130 adults on the waiting list for liver transplantation met the inclusion criteria in 2005 and 2006. Predictor and outcome variables were complete for 13,940 patients (99%). Characteristics of the patients are shown in Table 1Table 1
Characteristics of Registrants on the Waiting List for Liver Transplantation.. At registration on the waiting list, the median MELD score was 15 (range, 6 to 40) and the median serum sodium concentration was 137 mmol per liter (range, 112 to 168). Overall, 31% of the patients had hyponatremia (serum sodium concentration <135 mmol per liter), and in 2.5% of the patients, the serum sodium concentration was less than 125 mmol per liter.MELD Score, Serum Sodium, and Mortality
In 2005, a total of 422 patients died and 1781 underwent liver transplantation within 90 days after registration on the waiting list. As expected, there was a near-linear relation between the MELD score and mortality among patients on the waiting list. On average, the risk of death increased by 21% (hazard ratio, 1.21; 95% confidence interval [CI], 1.20 to 1.22; P<0.001) per unit increase in the MELD score.
Figure 1Figure 1
Serum Sodium Concentration and the Relative Risk of Death after Adjustment for the MELD Score. shows that a decrease in the serum sodium concentration was associated with an increase in the risk of death while patients were on the waiting list, even after adjustment for the MELD score. The most meaningful differential effect of hyponatremia on mortality appeared to occur at a serum sodium concentration between 125 and 140 mmol per liter. This effect was verified by model fitting: a Cox model with these upper and lower bounds for the sodium concentration was superior to the model with continuous, untruncated sodium values. The model fit did not improve by allowing the risk for patients with a serum sodium concentration of less than 123 mmol per liter to differ from the risk for patients with a serum sodium concentration of 123 to 127 mmol per liter, or by allowing the risk for patients with a serum sodium concentration of more than 142 mmol per liter to differ from the risk for those with a serum sodium concentration of 138 to 142 mmol per liter (data not shown). A Cox model, adjusted for the MELD score, showed an increase in the risk of death of 5% (hazard ratio, 1.05; 95% CI, 1.03 to 1.08; P<0.001) per unit decrease in the serum sodium concentration when the serum sodium concentration was between 125 and 140 mmol per liter.Effect of Serum Sodium at Different MELD Scores
The result of the multivariable Cox regression analysis for the interaction between the MELD score and the serum sodium concentration (i.e., the MELDNa score) is summarized by the following formula:
MELDNa = MELD − Na − [0.025 × MELD × (140 − Na)] + 140,
where the serum sodium concentration (Na) is bound between 125 and 140 mmol per liter. Like the MELD score, the MELDNa score is rounded to the nearest integer.
The result can also be depicted as the additional allocation points a patient would receive for a given MELD score and serum sodium concentration (Figure 2Figure 2
Computation of the MELDNa Score on the Basis of the MELD Score and the Serum Sodium Concentration.). Patients with hyponatremia could have up to 13 points added to their MELD score, which would equate their risk of death to the risk for patients with normal sodium concentrations. The majority of the patients in this study (61%) had serum sodium concentrations above 135 mmol per liter; for these patients, the MELDNa score was essentially identical to the MELD score. Similarly, for patients with MELD scores above 30, the effect of hyponatremia was quite small. However, for patients with moderate MELD scores, the effect could be substantial. For example, a patient with a MELD score of 10 and a serum sodium concentration of 125 mmol per liter would have a MELDNa score of 21 (i.e., 11 points added to the MELD score), because the risk of death would be equivalent to the risk for a patient with a MELD score of 21 and a normal serum sodium concentration.Calibration and Discrimination of the MELDNa Score
A total of 2159 patients underwent transplantation and 477 patients died within 90 days after registration in 2006; these data were used to examine the calibration and discrimination of the MELDNa score. Figure 3Figure 3
Observed and Predicted Probability of Death at 90 Days. compares the calibration of the MELD and MELDNa scores in predicting the probability of death at 90 days. The observed probability of death and the probability predicted by the MELDNa score based on the 2005 data are shown, as well as the observed probability of death and that predicted by the MELDNa and MELD scores based on the 2006 data. The probability of death predicted by the MELDNa score was similar to the observed probability for both data sets. As expected, the discrepancy was a bit larger for the validation data from 2006. More important, the 2006 data show that the mortality predicted by the MELDNa score matched the observed mortality at 90 days better than did the mortality predicted by the MELD score in virtually all deciles of MELD scores that were tested. The Hosmer–Lemeshow statistic (as modified by D'Agostino and Nam20 for survival data) was 17.8 for the MELDNa score and 51.3 for the MELD score. There was less discrepancy between the actual and predicted probabilities with the MELDNa score than with the MELD score (see the Supplementary Appendix for details).In this study, discrimination refers to the ability to rank patients correctly according to their risk of death. Discrimination of the MELD and MELDNa scores may be assessed by means of the C statistic, a conventional metric of discrimination, which was modestly, yet significantly higher with the MELDNa score than with the MELD score (0.883 vs. 0.868, P<0.001). Assessment of the integrated discrimination improvement (i.e., the average improvement in the predicted probability of death) indicated that the net improvement in the risk score — although numerically small and of uncertain clinical significance — was statistically significant (integrated discrimination improvement, 1.1%; P<0.001) (see the Supplementary Appendix).
The potential effect of the use of the MELDNa score in liver allocation is shown in Figure 4Figure 4
Distribution of MELD and MELDNa Scores among the 477 Patients Who Died while on the Waiting List, 2006., which shows how the 477 patients who died within 90 days after registration in 2006 would have been reclassified if the MELDNa score had been used instead of the MELD score. For 363 patients, the MELD and MELDNa scores were similar, whereas for 110 patients (23% of the patients who died), the difference between the MELDNa and MELD scores was sufficiently large that the priority for liver allocation might have been altered if the MELDNa score had been used. On the basis of the probabilities of transplantation with the use of the MELD score in 2006, we estimated that if the MELDNa score had been used for organ allocation, the incremental increase in the number of transplantations would have been 32, suggesting that 7% of the 477 deaths might have been prevented (Figure 4).Discussion
Since the MELD score was adopted in 2002 as the standard by which priority for liver allocation is determined, mortality among patients on the waiting list has decreased substantially in the United States.23 However, the MELD score may not accurately reflect the risk of death in some groups of patients. Previous studies have shown that one such group is patients with hyponatremia.15-18 Our study involved the entire waiting list of registrants in the United States; this large sample provided sufficient statistical power to accurately characterize and validate the interaction between the MELD score and the serum sodium concentration as predictors of mortality.16,18 Our data show that the effect of hyponatremia gradually diminished as the MELD score increased, as shown in Figure 2.
The current approach to liver transplantation in the United States is to prioritize the allocation of liver grafts on the basis of urgency (i.e., the estimated risk of death for a patient on the waiting list).24-29 In this study, we found that as compared with the MELD score, the MELDNa score provides better calibration and discrimination of the risk of death among candidates for liver transplantation; thus, use of the MELDNa score may reduce mortality among patients on the waiting list. Since the MELDNa score differs substantially from the MELD score only for patients with hyponatremia, the proportion of candidates for liver transplantation who would be affected by the use of this combined score would be modest. Among such patients, however, we found that the magnitude of the difference between the MELD score and the MELDNa score was often large enough to make a real difference in the probability of receiving a liver transplant and averting death (Figure 4). Common measures of discrimination such as the C statistic are insensitive to this difference, since they gauge only the proportion of patients whose ranks change, without consideration of the magnitude of the change in ranks. Our analysis suggests that as many as 7% of waiting-list deaths could be averted if the MELDNa score were used for liver allocation; this would project to 90 lives saved (7% of 1291 patients who died) for the period from 2005 to 2006. Although this may be a modest number, we believe that the use of the MELDNa score could be an important improvement in identifying a subgroup of patients with cirrhosis who have severe fluid retention and a high risk of death.
In our previous research in selected academic transplantation centers, the effect of the serum sodium concentration was modeled as a linear variable, with a lower bound for the serum sodium concentration of 120 mmol per liter and an upper bound of 135 mmol per liter.18 The current study, with a large sample that permitted formal testing of these lower and upper bounds, updates the range to 125 to 140 mmol per liter. This change is clinically preferable in considering the MELDNa score for liver allocation. Hyponatremia at the time of liver transplantation has been associated with increased morbidity (e.g., due to central pontine myelinolysis30-32) and mortality in the immediate postoperative period.33,34 Whether this association is attributable to hyponatremia itself or reflects the fact that patients with hyponatremia tend to be ill in general remains to be determined. Nonetheless, an allocation system that excessively favors patients with severe hyponatremia may diminish the overall outcome after liver transplantation. Ultimately, once an organ is allocated to a patient with hyponatremia, it should remain the responsibility of the individual physicians to determine whether the patient is at too high a risk to undergo liver transplantation.
Our analysis has limitations. First, the data on serum sodium concentrations were obtained at a single time point — when a patient was placed on the waiting list. Serum sodium concentrations may vary depending on factors such as the volume status and use or nonuse of diuretics. Since the data from the waiting list were collected without a specific protocol for these variables, the data on serum sodium concentrations may entail a significant degree of variability. However, published data and common clinical observations indicate that hyponatremia in patients with cirrhosis is difficult to alter.35,36 In addition, the consistency of the effect of the serum sodium concentration on short-term mortality between the 2005 and 2006 data ensures the validity of our observation. Second, this analysis is based on a waiting-list registry, rather than on a database specifically created for the study, which makes heterogeneity in the data inevitable.37-40 Nonetheless, since the OPTN conducts periodic, mandatory audits of data at each center, we believe that most of our data are accurate. Third, we held the MELD score intact rather than refitting coefficients for its components, since our primary objective was to define the relationships among the MELD score, the serum sodium concentration, and short-term mortality in our patients. Having been validated and used extensively, the MELD score is familiar to liver-transplantation personnel. However, if the MELDNa score is to be adopted for organ allocation, further adjustment of the model may be required before implementation.
Despite these shortcomings, we believe our analysis shows that the MELDNa score may provide significantly better prediction of mortality among registrants on the waiting list for liver transplantation. We think that with the priority for organ allocation based on urgency for liver transplantation, adoption of the MELDNa score should be tested to see whether it reduces mortality among patients on the waiting list.
Supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (DK-34238, DK-61617, and DK-76565) and the Palumbo Foundation and the Jan Albrecht Commitment to Clinical Research in Liver Disease Award from the American Liver Foundation.
No potential conflict of interest relevant to this article was reported.
Source Information
From the Division of Gastroenterology and Hepatology (W.R.K., R.H.W., P.S.K.) and the Division of Biostatistics (W.K.K., J.T.B., T.M.T.), Mayo Clinic College of Medicine, Rochester, MN; the Division of Gastroenterology and GI Health Outcomes, Policy and Economics Research Program, University of California at San Francisco, San Francisco (S.W.B.); and the United Network for Organ Sharing, Richmond, VA (E.E.).
Address reprint requests to Dr. Kim at the Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First St., Rochester, MN 55905, or at kim.ray@mayo.edu.
- References
References
1
Malinchoc M ,Kamath PS ,Gordon FD ,Peine CJ ,Rank J ,ter Borg PC . A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864-871
CrossRef | Web of Science | Medline2
Freeman RB Jr ,Wiesner RH ,Harper A , et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002;8:851-858
CrossRef | Web of Science | Medline3
Wiesner RH ,McDiarmid SV ,Kamath PS , et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001;7:567-580
CrossRef | Web of Science | Medline4
Kamath PS ,Wiesner RH ,Malinchoc M , et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-470
CrossRef | Web of Science | Medline5
Gines A ,Escorsell A ,Gines P , et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-236
Web of Science | Medline6
Porcel A ,Diaz F ,Rendon P ,Macias M ,Martin-Herrera L ,Giron-Gonzalez JA . Dilutional hyponatremia in patients with cirrhosis and ascites. Arch Intern Med 2002;162:323-328
CrossRef | Web of Science | Medline7
Arroyo V ,Colmenero J . Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003;38:Suppl 1:S69-S89
CrossRef | Web of Science | Medline8
Cosby RL ,Yee B ,Schrier RW . New classification with prognostic value in cirrhotic patients. Miner Electrolyte Metab 1989;15:261-266
Medline9
Borroni G ,Maggi A ,Sangiovanni A ,Cazzaniga M ,Salerno F . Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients. Dig Liver Dis 2000;32:605-610
CrossRef | Medline10
Fernandez-Esparrach G ,Sanchez-Fueyo A ,Gines P , et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001;34:46-52
CrossRef | Web of Science | Medline11
Llach J ,Gines P ,Arroyo V , et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988;94:482-487
Web of Science | Medline12
Shear L ,Kleinerman J ,Gabuzda GJ . Renal failure in patients with cirrhosis of the liver. I. Clinical and pathologic characteristics. Am J Med 1965;39:184-198
CrossRef | Web of Science | Medline13
Earley LE ,Sanders CA . The effect of changing serum osmolality on the release of antidiuretic hormone in certain patients with decompensated cirrhosis of the liver and low serum osmolality. J Clin Invest 1959;38:545-550
CrossRef | Web of Science | Medline14
Arroyo V ,Rodes J ,Gutierrez-Lizarraga MA ,Revert L . Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis 1976;21:249-256
CrossRef | Medline15
Ruf AE ,Kremers WK ,Chavez LL ,Descalzi VI ,Podesta LG ,Villamil FG . Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005;11:336-343
CrossRef | Web of Science | Medline16
Heuman DM ,Abou-Assi SG ,Habib A , et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004;40:802-810
CrossRef | Web of Science | Medline17
Biggins SW ,Rodriguez HJ ,Bacchetti P ,Bass NM ,Roberts JP ,Terrault NA . Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005;41:32-39
CrossRef | Web of Science | Medline18
Biggins SW ,Kim WR ,Terrault NA , et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006;130:1652-1660
CrossRef | Web of Science | Medline19
D'Agostino RB ,Grundy S ,Sullivan LM ,Wilson P . Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286:180-187
CrossRef | Web of Science | Medline20
D'Agostino RB, Nam B-H. Evaluation of the performance of survival analysis models: discrimination and calibration measures. In: Balakrishnan N, Rao CR, eds. Advances in survival analysis. Amsterdam: Elsevier, 2004:1-25.
21
Pencina MJ ,D'Agostino RB ,D'Agostino RB ,Vasan RS . Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-172
CrossRef | Web of Science | Medline22
Heagerty PJ ,Zheng Y . Survival model predictive accuracy and ROC curves. Biometrics 2005;61:92-105
CrossRef | Web of Science | Medline23
Kamath PS ,Kim WR . The Model for End-Stage Liver Disease (MELD). Hepatology 2007;45:797-805
CrossRef | Web of Science | Medline24
Onaca N ,Levy MF ,Netto GJ , et al. Pretransplant MELD score as a predictor of outcome after liver transplantation for chronic hepatitis C. Am J Transplant 2003;3:626-630
CrossRef | Web of Science | Medline25
Saab S ,Wang V ,Ibrahim AB , et al. MELD score predicts 1-year patient survival post-orthotopic liver transplantation. Liver Transpl 2003;9:473-476
CrossRef | Web of Science | Medline26
Freeman RB ,Harper A ,Edwards EB . Excellent liver transplant survival rates under the MELD/PELD system. Transplant Proc 2005;37:585-588
CrossRef | Web of Science | Medline27
Ghobrial RM ,Steadman R ,Gornbein J , et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001;234:384-394
CrossRef | Web of Science | Medline28
Nair S ,Verma S ,Thuluvath PJ . Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002;35:1179-1185
CrossRef | Web of Science | Medline29
Rimola A ,Gavaler JS ,Schade RR ,el-Lankany S ,Starzl TE ,Van Thiel DH . Effects of renal impairment on liver transplantation. Gastroenterology 1987;93:148-156
Web of Science | Medline30
Wijdicks EF ,Blue PR ,Steers JL ,Wiesner RH . Central pontine myelinolysis with stupor alone after orthotopic liver transplantation. Liver Transpl Surg 1996;2:14-16
CrossRef | Medline31
Bronster DJ ,Emre S ,Boccagni P ,Sheiner PA ,Schwartz ME ,Miller CM . Central nervous system complications in liver transplant recipients -- incidence, timing, and long-term follow-up. Clin Transplant 2000;14:1-7
CrossRef | Web of Science | Medline32
Abbasoglu O ,Goldstein RM ,Vodapally MS , et al. Liver transplantation in hyponatremic patients with emphasis on central pontine myelinolysis. Clin Transplant 1998;12:263-269
Web of Science | Medline33
Londono M ,Guevara M ,Rimola A , et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 2006;130:1135-1143
CrossRef | Web of Science | Medline34
Dawwas MF ,Lewsey JD ,Neuberger JM ,Gimson AE . The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transpl 2007;13:1115-1124
CrossRef | Web of Science | Medline35
Gerbes AL ,Gulberg V ,Gines P , et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003;124:933-939
CrossRef | Web of Science | Medline36
Wong F ,Blei AT ,Blendis LM ,Thuluvath PJ . A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003;37:182-191
CrossRef | Web of Science | Medline37
Tripodi A ,Chantarangkul V ,Primignani M , et al. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 2007;46:520-527
CrossRef | Web of Science | Medline38
Bellest L ,Eschwege V ,Poupon R ,Chazouilleres O ,Robert A . A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. Hepatology 2007;46:528-534
CrossRef | Web of Science | Medline39
Trotter JF ,Brimhall B ,Arjal R ,Phillips C . Specific laboratory methodologies achieve higher Model for Endstage Liver Disease (MELD) scores for patients listed for liver transplantation. Liver Transpl 2004;10:995-1000
CrossRef | Web of Science | Medline40
Trotter JF ,Olson J ,Lefkowitz J ,Smith AD ,Arjal R ,Kenison J . Changes in international normalized ratio (INR) and model for endstage liver disease (MELD) based on selection of clinical laboratory. Am J Transplant 2007;7:1624-1628
CrossRef | Web of Science | Medline
- Citing Articles (114)
Citing Articles
1
Zheng Zhang, Hu Lin, Ming Shi, Ruonan Xu, Junliang Fu, Jiyun Lv, Liming Chen, Sa Lv, Yuanyuan Li, Shuangjie Yu, Hua Geng, Lei Jin, George K K Lau, Fu-Sheng Wang. (2012) Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. Journal of Gastroenterology and Hepatology 27, 112-120
CrossRef2
Laurence S. Magder, Arie Regev, Ayse L. Mindikoglu. (2012) Comparison of seven liver allocation models with respect to lives saved among patients on the liver transplant waiting list. Transplant Internationalno-no
CrossRef3
Chia-Yang Hsu, Yun-Hsuan Lee, Yi-Hsiang Huang, Cheng-Yuan Hsia, Chien-Wei Su, Han-Chieh Lin, Rheun-Chuan Lee, Yi-You Chiou, Fa-Yauh Lee, Teh-Ia Huo, Shou-Dong Lee. (2012) Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact, and staging strategy. Hepatology International
CrossRef4
Danielle Brandman, Scott W. Biggins, Bilal Hameed, John P. Roberts, Norah A. Terrault. (2012) Pretransplant severe hepatic encephalopathy, peritransplant sodium and post-liver transplantation morbidity and mortality. Liver International 32:1, 158-164
CrossRef5
Rodrigo Cavallazzi, Olatilewa O. Awe, Tajender S. Vasu, Amyn Hirani, Urvashi Vaid, Benjamin E. Leiby, Walter K. Kraft, Gregory C. Kane. (2012) Model for End-Stage Liver Disease score for predicting outcome in critically ill medical patients with liver cirrhosis. Journal of Critical Care
CrossRef6
D. G. N. Craig, T. W. D. J. Reid, E. C. Wright, K. G. Martin, J. S. Davidson, P. C. Hayes, K. J. Simpson. (2012) The sequential organ failure assessment (SOFA) score is prognostically superior to the model for end-stage liver disease (MELD) and MELD variants following paracetamol (acetaminophen) overdose. Alimentary Pharmacology & Therapeuticsn/a-n/a
CrossRef7
Eric Levesque, Emir Hoti, Daniel Azoulay, Philippe Ichaï, Houssam Habouchi, Denis Castaing, Didier Samuel, Faouzi Saliba. (2012) Prospective evaluation of the prognostic scores for cirrhotic patients admitted to an Intensive Care Unit. Journal of Hepatology 56:1, 95-102
CrossRef8
Guadalupe Garcia-Tsao. 2012. Ascites. , 283-295.
CrossRef9
Scott W. Biggins. 2012. Pretransplant Evaluation and Care. , 837-852.
CrossRef10
Gustavo Pereira, Mónica Guevara, Claudia Fagundes, Elsa Solá, Ezequiel Rodríguez, Javier Fernández, Marco Pavesi, Vicente Arroyo, Pere Ginès. (2012) Renal failure and hyponatremia in patients with cirrhosis and skin and soft tissue infection. A retrospective study. Journal of Hepatology
CrossRef11
Juliana Ribeiro de Carvalho, Cristiane Alves Villela-Nogueira, Ronir Raggio Luiz, Paula Lustosa Guzzo, Juliana Maria da Silva Rosa, Eduardo Rocha, Henrique Sérgio Moraes Coelho, Renata de Mello Perez. (2012) Acute Kidney Injury Network Criteria as a Predictor of Hospital Mortality in Cirrhotic Patients With Ascites. Journal of Clinical Gastroenterology1
CrossRef12
J. Herbert Patterson. (2011) Hyponatremia's Impact on Patients and Health Systems. Hospital Pharmacy 46:-1, S3-S10
CrossRef13
Constantine Frangakis, Jean-Francois Geschwind, Daniel Kim, Yong Chen, Ayman Koteish, Kelvin Hong, Eleni Liapi, Christos S. Georgiades. (2011) Chemoembolization Decreases Drop-Off Risk of Hepatocellular Carcinoma Patients on the Liver Transplant List. CardioVascular and Interventional Radiology 34:6, 1254-1261
CrossRef14
J. Herbert Patterson, Kirkwood F. Adams, Theresa Human, Denise H. Rhoney. (2011) Case Studies in Hypervolemic Hyponatremia. Hospital Pharmacy 46:-1, S39-S44
CrossRef15
Manuel L. Rodríguez-Perálvarez, Jose Luis Montero, Manuel De la Mata García. (2011) Current challenges and future trends in liver transplantation. Digestive and Liver Disease Supplements 5:1, 2-5
CrossRef16
Piergiorgio Marchetti, Costanza D'Avanzo, Raffaele Orsato, Sara Montagnese, Sami Schiff, Peter W. Kaplan, Francesco Piccione, Carlo Merkel, Angelo Gatta, Giovanni Sparacino, Gianna Maria Toffolo, Piero Amodio. (2011) Electroencephalography in Patients With Cirrhosis. Gastroenterology 141:5, 1680-1689.e2
CrossRef17
Sumeet K. Asrani, W. Ray Kim. (2011) Model for End-Stage Liver Disease: End of the First Decade. Clinics in Liver Disease 15:4, 685-698
CrossRef18
Chandan Guha, Brian D. Kavanagh. (2011) Hepatic Radiation Toxicity: Avoidance and Amelioration. Seminars in Radiation Oncology 21:4, 256-263
CrossRef19
Kari A. Martin, J. Michael Bostwick, Hugo E. Vargas. (2011) Liver Transplant Case Report: Transgenderism and Liver Transplantation. International Journal of Transgenderism 13:1, 45-49
CrossRef20
Andrés Cárdenas, Pere Ginès, Paul Marotta, Frank Czerwiec, John Oyuang, Mónica Guevara, Nezam H Afdhal. (2011) Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology
CrossRef21
Claire Francoz, Jacques Belghiti, Denis Castaing, Olivier Chazouillères, Jean-Charles Duclos-Vallée, Christophe Duvoux, Jan Lerut, Yves-Patrice Le Treut, Richard Moreau, Ameet Mandot, Georges Pageaux, Didier Samuel, Dominique Thabut, Dominique Valla, François Durand. (2011) Model for end-stage liver disease exceptions in the context of the french model for end-stage liver disease score-based liver allocation system. Liver Transplantation 17:10, 1137-1151
CrossRef22
Hongyu Zhang, Zhiyu Chen, Ping Bie. (2011) Bone Marrow–Derived Mesenchymal Stem Cells as Immunosuppressants in Liver Transplantation: A Review of Current Data. Transfusion Medicine Reviews
CrossRef23
Melissa Palmer. 2011. Nutrition and Liver Transplantation. , 159-170.
CrossRef24
Jacek B. Cywinski, Edward J. Mascha, Jing You, Daniel I. Sessler, Leonardo Kapural, Maged Argalious, Brian M. Parker. (2011) Pre-transplant MELD and sodium MELD scores are poor predictors of graft failure and mortality after liver transplantation. Hepatology International 5:3, 841-849
CrossRef25
Shaorui Hao, Jiaojiao Xin, Jiangshan Lian, Qing Xie, Deying Chen, Yongzheng Guo, Yingfeng Lu, Guoping Sheng, Wei Xu, Jianrong Huang, Lanjuan Li. (2011) Establishing a metabolomic model for the prognosis of hepatitis B virus-induced acute-on-chronic liver failure treated with different liver support systems. Metabolomics 7:3, 400-412
CrossRef26
Aldo J. Montano–Loza, Judith Meza–Junco, Carla M.M. Prado, Jessica R. Lieffers, Vickie E. Baracos, Vincent G. Bain, Michael B. Sawyer. (2011) Muscle Wasting Is Associated With Mortality in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology
CrossRef27
I. Tzoulaki, G. Liberopoulos, J. P. A. Ioannidis. (2011) Use of reclassification for assessment of improved prediction: an empirical evaluation. International Journal of Epidemiology 40:4, 1094-1105
CrossRef28
Kerri Barber, Susanna Madden, Joanne Allen, Dave Collett, James Neuberger, Alexander Gimson. (2011) Elective Liver Transplant List Mortality: Development of a United Kingdom End-Stage Liver Disease Score. Transplantation 92:4, 469-476
CrossRef29
Ewout J Hoorn, Fernando Rivadeneira, Joyce BJ van Meurs, Gijsbertus Ziere, Bruno HCh Stricker, Albert Hofman, Huibert AP Pols, Robert Zietse, André G Uitterlinden, M Carola Zillikens. (2011) Mild hyponatremia as a risk factor for fractures: The rotterdam study. Journal of Bone and Mineral Research 26:8, 1822-1828
CrossRef30
Maryam Moini, Mohammad Kazem Hoseini-Asl, Seyed Alireza Taghavi, Mohammad M. Sagheb, Saman Nikeghbalian, Heshmatalah Salahi, Ali Bahador, Motahareh Motazedian, Peyman Jafari, Sayed Ali Malek-Hosseini. (2011) Hyponatremia a valuable predictor of early mortality in patients with cirrhosis listed for liver transplantation. Clinical Transplantation 25:4, 638-645
CrossRef31
Mauro Bernardi, Stefano Gitto, Maurizio Biselli. (2011) The MELD score in patients awaiting liver transplant: Strengths and weaknesses. Journal of Hepatology 54:6, 1297-1306
CrossRef32
Giuseppe Tonini, Maria Elisabetta Fratto, Marco Imperatori, Francesco Pantano, Bruno Vincenzi, Daniele Santini. (2011) Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence. Expert Review of Anticancer Therapy 11:6, 921-930
CrossRef33
Jacqueline G. O'Leary, James F. Trotter. (2011) Is MELD Fit Enough?. Gastroenterology 140:7, 1871-1874
CrossRef34
Michael D. Leise, W. Ray Kim, Walter K. Kremers, Joseph J. Larson, Joanne T. Benson, Terry M. Therneau. (2011) A Revised Model for End-Stage Liver Disease Optimizes Prediction of Mortality Among Patients Awaiting Liver Transplantation. Gastroenterology 140:7, 1952-1960
CrossRef35
Christophe Bureau, Sophie Métivier, Mario D’Amico, Jean Marie Péron, Philippe Otal, Juan Carlos Garcia Pagan, Valérie Chabbert, Carine Chagneau-Derrode, Bogdan Procopet, Hervé Rousseau, Jaume Bosch, Jean Pierre Vinel. (2011) Serum bilirubin and platelet count: A simple predictive model for survival in patients with refractory ascites treated by TIPS. Journal of Hepatology 54:5, 901-907
CrossRef36
Joanna A. Leithead, Suzanne M. MacKenzie, James W. Ferguson, Peter C. Hayes. (2011) Is estimated glomerular filtration rate superior to serum creatinine in predicting mortality on the waiting list for liver transplantation?. Transplant International 24:5, 482-488
CrossRef37
Saleh A Alqahtani, Anne M Larson. (2011) Adult liver transplantation in the USA. Current Opinion in Gastroenterology 27:3, 240-247
CrossRef38
P. Aiden McCormick. 2011. Hepatic Cirrhosis. , 103-120.
CrossRef39
Guadalupe Garcia-Tsao. 2011. Ascites. , 210-233.
CrossRef40
Marcus Bahra, Peter Neuhaus. (2011) Liver transplantation in the high MELD era: a fair chance for everyone?. Langenbeck's Archives of Surgery 396:4, 461-465
CrossRef41
Konstantin Kazankov, Peter Holland-Fischer, Niels H. Andersen, Peter Torp, Erik Sloth, Niels K. Aagaard, Hendrik Vilstrup. (2011) Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging. Liver International 31:4, 534-540
CrossRef42
Michael L Moritz, Juan C Ayus. (2011) Intravenous fluid management for the acutely ill child. Current Opinion in Pediatrics 23:2, 186-193
CrossRef43
Robert P. Myers, Abdel Aziz M. Shaheen, Alexander I. Aspinall, Robert R. Quinn, Kelly W. Burak. (2011) Gender, renal function, and outcomes on the liver transplant waiting list: Assessment of revised MELD including estimated glomerular filtration rate. Journal of Hepatology 54:3, 462-470
CrossRef44
Chia-Hung Chen, Chuen-Ming Shih, Jen-Wei Chou, Yi-Heng Liu, Liang-Wen Hang, Te-Chun Hsia, Wu-Huei Hsu, Chih-Yen Tu. (2011) Outcome predictors of cirrhotic patients with spontaneous bacterial empyema. Liver International 31:3, 417-424
CrossRef45
Jeannette Guarner, Jay Hochman, Ekaterina Kurbatova, Richard Mullins. (2011) Study of Outcomes Associated with Hyponatremia and Hypernatremia in Children. Pediatric and Developmental Pathology 14:2, 117-123
CrossRef46
Amy N. Sussman, Thomas D. Boyer. (2011) Management of Refractory Ascites and Hepatorenal Syndrome. Current Gastroenterology Reports 13:1, 17-25
CrossRef47
Herold J. Metselaar, Jan Lerut, Geert Kazemier. (2011) The true merits of liver allocation according to MELD scores: survival after transplantation tells only one side of the story. Transplant International 24:2, 132-133
CrossRef48
Ma Somsouk, Rachel Kornfield, Eric Vittinghoff, John M. Inadomi, Scott W. Biggins. (2011) Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk. Liver Transplantation 17:2, 129-136
CrossRef49
Mark Fox, Jenny Fox, Mervyn Davies. (2011) Diagnosis and management of chronic liver disease in older people. Reviews in Clinical Gerontology 21:01, 1-15
CrossRef50
Marta Martín–Llahí, Mónica Guevara, Aldo Torre, Claudia Fagundes, Tea Restuccia, Rosa Gilabert, Elsa Solá, Gustavo Pereira, Marcella Marinelli, Marco Pavesi, Javier Fernández, Juan Rodés, Vicente Arroyo, Pere Ginès. (2011) Prognostic Importance of the Cause of Renal Failure in Patients With Cirrhosis. Gastroenterology 140:2, 488-496.e4
CrossRef51
Hannes Neeff, Dimitri Mariaskin, Hans-Christian Spangenberg, Ulrich T. Hopt, Frank Makowiec. (2011) Perioperative Mortality After Non-hepatic General Surgery in Patients with Liver Cirrhosis: an Analysis of 138 Operations in the 2000s Using Child and MELD Scores. Journal of Gastrointestinal Surgery 15:1, 1-11
CrossRef52
Hyun Chin Cho, Han Young Jung, Dong Hyun Sinn, Moon Seok Choi, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo, Seon Woo Kim, Joon Hyeok Lee. (2011) Mortality after surgery in patients with liver cirrhosis. European Journal of Gastroenterology & Hepatology 23:1, 51-59
CrossRef53
Evangelos Cholongitas, Giacomo Germani, Andrew K. Burroughs. (2010) Prioritization for liver transplantation. Nature Reviews Gastroenterology & Hepatology 7:12, 659-668
CrossRef54
Elsa Solà, Pere Ginès. (2010) Renal and circulatory dysfunction in cirrhosis: Current management and future perspectives. Journal of Hepatology 53:6, 1135-1145
CrossRef55
Elsa Solà, Sabela Lens, Mónica Guevara, Marta Martín-Llahí, Claudia Fagundes, Gustavo Pereira, Marco Pavesi, Javier Fernández, Juan González-Abraldes, Angels Escorsell, Antoni Mas, Jaume Bosch, Vicente Arroyo, Pere Ginès. (2010) Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. Hepatology 52:5, 1783-1790
CrossRef56
Vincent Das, Pierre-Yves Boelle, Arnaud Galbois, Bertrand Guidet, Eric Maury, Nicolas Carbonell, Richard Moreau, Georges Offenstadt. (2010) Cirrhotic patients in the medical intensive care unit: Early prognosis and long-term survival*. Critical Care Medicine 38:11, 2108-2116
CrossRef57
Mashaal Dhir, Lynette M. Smith, Fred Ullrich, Premila D. Leiphrakpam, Quan P. Ly, Aaron R. Sasson, Chandrakanth Are. (2010) Pre-operative Nomogram to Predict Risk of Peri-operative Mortality following Liver Resections for Malignancy. Journal of Gastrointestinal Surgery 14:11, 1770-1781
CrossRef58
Claire Francoz, Dominique Prié, Wael AbdelRazek, Richard Moreau, Ameet Mandot, Jacques Belghiti, Dominique Valla, François Durand. (2010) Inaccuracies of creatinine and creatinine-based equations in candidates for liver transplantation with low creatinine: Impact on the model for end-stage liver disease score. Liver Transplantation 16:10, 1169-1177
CrossRef59
Nayantara Coelho-Prabhu, Patrick S. Kamath. 2010. Portal Hypertension. , 125-143.
CrossRef60
Pere Ginès, Andrés Cárdenas, Vicente Arroyo, Juan Rodés. 2010. Ascites, Hepatorenal Syndrome and Spontaneous Bacterial Peritonitis. , 619-635.
CrossRef61
(2010) EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. Journal of Hepatology 53:3, 397-417
CrossRef62
Umberto Cillo, Alessandro Vitale, Michael L. Volk, Anna Chiara Frigo, Francesco Grigoletto, Alberto Brolese, Giacomo Zanus, Francesco D’Amico, Fabio Farinati, Patrizia Burra, Francesco Russo, Paolo Angeli, Davide F. D’Amico. (2010) The survival benefit of liver transplantation in hepatocellular carcinoma patients. Digestive and Liver Disease 42:9, 642-649
CrossRef63
Thomas Sersté, Christian Melot, Claire Francoz, François Durand, Pierre-Emmanuel Rautou, Dominique Valla, Richard Moreau, Didier Lebrec. (2010) Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 52:3, 1017-1022
CrossRef64
Maurizio Biselli, Stefano Gitto, Annagiulia Gramenzi, Roberto Di Donato, Lucia Brodosi, Matteo Ravaioli, Gian Luca Grazi, Antonio Daniele Pinna, Pietro Andreone, Mauro Bernardi. (2010) Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: Which is the winner?. Liver Transplantation 16:8, 964-973
CrossRef65
Ewout J Hoorn, Robert Zietse. (2010) Vasopressin-receptor antagonists. Future Cardiology 6:4, 523-534
CrossRef66
Michael L. Moritz, Juan Carlos Ayus. (2010) New aspects in the pathogenesis, prevention, and treatment of hyponatremic encephalopathy in children. Pediatric Nephrology 25:7, 1225-1238
CrossRef67
Chia-Yang Hsu, Yi-Hsiang Huang, Cheng-Yuan Hsia, Chien-Wei Su, Han-Chieh Lin, Che-Chuan Loong, Yi-You Chiou, Jen-Huey Chiang, Pui-Ching Lee, Teh-Ia Huo, Shou-Dong Lee. (2010) A new prognostic model for hepatocellular carcinoma based on total tumor volume: The Taipei Integrated Scoring system. Journal of Hepatology 53:1, 108-117
CrossRef68
Elizabeth Ross, Samuel H. Sigal. (2010) Managing hyponatremia in cirrhosis. Journal of Hospital Medicine 5:S3, S8-S17
CrossRef69
Mark T Keegan, David R Wright. (2010) Sodium, potassium and glucose management in organ transplantation. Current Opinion in Organ Transplantation 15:3, 383-389
CrossRef70
Paul M. McKie, Alessandro Cataliotti, Brian D. Lahr, Fernando L. Martin, Margaret M. Redfield, Kent R. Bailey, Richard J. Rodeheffer, John C. Burnett. (2010) The Prognostic Value of N-Terminal Pro–B-Type Natriuretic Peptide for Death and Cardiovascular Events in Healthy Normal and Stage A/B Heart Failure Subjects. Journal of the American College of Cardiology 55:19, 2140-2147
CrossRef71
Sumeet K Asrani, W Ray Kim. (2010) Organ allocation for chronic liver disease: model for end-stage liver disease and beyond. Current Opinion in Gastroenterology 26:3, 209-213
CrossRef72
Stevan A. Gonzalez, James F. Trotter. (2010) Renal function and MELD: Being direct is better. Journal of Hepatology 52:5, 622-623
CrossRef73
Takasuke Fukuhara, Toru Ikegami, Kazutoyo Morita, Kenji Umeda, Shigeru Ueda, Shigeyuki Nagata, Keishi Sugimachi, Tomonobu Gion, Tomoharu Yoshizumi, Yuji Soejima, Akinobu Taketomi, Yoshihiko Maehara. (2010) Impact of preoperative serum sodium concentration in living donor liver transplantation. Journal of Gastroenterology and Hepatology 25:5, 978-984
CrossRef74
Nicole M. Walker, Katherine A. Stuart, Rebecca J. Ryan, Shireena Desai, Sammy Saab, Jennifer A. Nicol, Linda M. Fletcher, Darrell H. G. Crawford. (2010) Serum ferritin concentration predicts mortality in patients awaiting liver transplantation. Hepatology 51:5, 1683-1691
CrossRef75
Andrew T Burr, Shimul A Shah. (2010) Disparities in organ allocation and access to liver transplantation in the USA. Expert Review of Gastroenterology & Hepatology 4:2, 133-140
CrossRef76
Young-Suk Lim, Timothy S. Larson, Joanne T. Benson, Patrick S. Kamath, Walter K. Kremers, Terry M. Therneau, W. Ray Kim. (2010) Serum sodium, renal function, and survival of patients with end-stage liver disease. Journal of Hepatology 52:4, 523-528
CrossRef77
Andreas Kortgen, Peter Recknagel, Michael Bauer. (2010) How to assess liver function?. Current Opinion in Critical Care 16:2, 136-141
CrossRef78
A N Jeppesen, H K Jensen, F Donskov, N Marcussen, H von der Maase. (2010) Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma. British Journal of Cancer 102:5, 867-872
CrossRef79
Philipp Dutkowski, Olivier De Rougemont, Beat Müllhaupt, Pierre—Alain Clavien. (2010) Current and Future Trends in Liver Transplantation in Europe. Gastroenterology 138:3, 802-809.e4
CrossRef80
Douglas M. Heuman. (2010) Hyponatremia in Cirrhosis Answers and Questions. Journal of Clinical Gastroenterology 44:3, 157-158
CrossRef81
Chang-Chyi Jenq, Ming-Hung Tsai, Ya-Chung Tian, Ming-Yang Chang, Chan-Yu Lin, Jau-Min Lien, Yung-Chang Chen, Ji-Tseng Fang, Pan-Chi Chen, Chih-Wei Yang. (2010) Serum Sodium Predicts Prognosis in Critically Ill Cirrhotic Patients. Journal of Clinical Gastroenterology 44:3, 220-226
CrossRef82
Rebecca G. Carey, John C. Bucuvalas, William F. Balistreri, Todd G. Nick, Frederick R. Ryckman, Nada Yazigi. (2010) Hyponatremia increases mortality in pediatric patients listed for liver transplantation. Pediatric Transplantation 14:1, 115-120
CrossRef83
C.-Y. Hsu, H.-C. Lin, Y.-H. Huang, C.-W. Su, F.-Y. Lee, T.-I. Huo, P.-C. Lee, J.-Y. Lee, S.-D. Lee. (2010) Comparison of the model for end-stage liver disease (MELD), MELD-Na and MELDNa for outcome prediction in patients with acute decompensated hepatitis. Digestive and Liver Disease 42:2, 137-142
CrossRef84
Patrick G. Northup, Curtis K. Argo, Mihir R. Bakhru, Timothy M. Schmitt, Carl L. Berg, Mitchell H. Rosner. (2010) Pretransplant predictors of recovery of renal function after liver transplantation. Liver TransplantationNA-NA
CrossRef85
Zhiyong Guo, Xiaoshun He, Linwei Wu, Weiqiang Ju, Anbin Hu, Qiang Tai, Dongping Wang, Yi Ma, Guodong Wang, Xiaofeng Zhu, Jiefu Huang. (2010) Model for end-stage liver disease versus the Child-Pugh score in predicting the post-transplant 3-month and 1-year mortality in a cohort of Chinese recipients. Surgery Today 40:1, 38-45
CrossRef86
Mi Yeon Chung, Dae Won Jun, Su Ah Sung. (2010) Diagnostic value of cystatin C for predicting acute kidney injury in patients with liver cirrhosis. The Korean Journal of Hepatology 16:3, 301
CrossRef87
Ahmed Elsayem, Masanori Mori, Henrique A. Parsons, Mark F. Munsell, David Hui, Marvin O. Delgado-Guay, Timotheos Paraskevopoulos, Nada A. Fadul, Eduardo Bruera. (2010) Predictors of inpatient mortality in an acute palliative care unit at a comprehensive cancer center. Supportive Care in Cancer 18:1, 67-76
CrossRef88
Darrell HG Crawford, Katherine Stuart. (2009) Adding serum sodium to model for end-stage liver disease: Identifying those most at risk. Journal of Gastroenterology and Hepatology 24:12, 1804-1806
CrossRef89
(2009) Documento de consenso de la Sociedad Española de Trasplante Hepático. Lista de espera, trasplante pediátrico e indicadores de calidad. Gastroenterología y Hepatología 32:10, 702-716
CrossRef90
(2009) Documento de consenso de la Sociedad Española de Trasplante Hepático. Lista de espera, trasplante pediátrico e indicadores de calidad. Cirugía Española 86:6, 331-345
CrossRef91
Jennifer Guy, Ma Somsouk, Stephen Shiboski, Robert Kerlan, John M. Inadomi, Scott W. Biggins. (2009) New Model for End Stage Liver Disease Improves Prognostic Capability After Transjugular Intrahepatic Portosystemic Shunt. Clinical Gastroenterology and Hepatology 7:11, 1236-1240
CrossRef92
Michael R. Charlton, William J. Wall, Akinlolu O. Ojo, Pere Ginés, Stephen Textor, Fuad S. Shihab, Paul Marotta, Marcelo Cantarovich, James D. Eason, Russell H. Wiesner, Michael A. Ramsay, Juan C. Garcia-Valdecasas, James M. Neuberger, Sandy Feng, Connie L. Davis, Thomas A. Gonwa, . (2009) Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transplantation 15:11, S1-S34
CrossRef93
Hui-Chun Huang, Fa-Yauh Lee, Teh-Ia Huo. (2009) Major adverse events, pretransplant assessment and outcome prediction. Journal of Gastroenterology and Hepatology 24:11, 1716-1724
CrossRef94
Jacqueline G. O'Leary, Gary L. Davis. (2009) Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease. Liver Transplantation 15:10, 1325-1329
CrossRef95
M. SOMSOUK, J. GUY, S. W. BIGGINS, E. VITTINGHOFF, M. A. KOHN, J. M. INADOMI. (2009) Ascites improves upon plus serum sodium model for end-stage liver disease (MELD) for predicting mortality in patients with advanced liver disease. Alimentary Pharmacology & Therapeutics 30:7, 741-748
CrossRef96
S. Gitto, S. Lorenzini, M. Biselli, F. Conti, P. Andreone, M. Bernardi. (2009) Allocation priority in non-urgent liver transplantation: An overview of proposed scoring systems. Digestive and Liver Disease 41:10, 700-706
CrossRef97
Parul Dureja, Michael R. Lucey, Kris Kowdley, Geoffrey McCaughan, Christian Trautwein. (2009) Disparities in liver transplantation in the post-model for end-stage liver disease era: Are we there yet?. Hepatology 50:3, 981-984
CrossRef98
Xiao-Hui Lv, Hong-Bo Liu, Ying Wang, Bing-Yuan Wang, Min Song, Ming-Jun Sun. (2009) Validation of model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor in patients with cirrhosis. Journal of Gastroenterology and Hepatology 24:9, 1547-1553
CrossRef99
Sushrut S. Waikar, David B. Mount, Gary C. Curhan. (2009) Mortality after Hospitalization with Mild, Moderate, and Severe Hyponatremia. The American Journal of Medicine 122:9, 857-865
CrossRef100
Faisal A. Arain, Mahyar Khaleghi, Kent R. Bailey, Brian D. Lahr, Thom W. Rooke, Iftikhar J. Kullo. (2009) White Blood Cell Count Predicts All-Cause Mortality in Patients with Suspected Peripheral Arterial Disease. The American Journal of Medicine 122:9, 874.e1-874.e7
CrossRef101
Michael R. Lucey, Douglas E. Schaubel, Mary K. Guidinger, Santiago Tome, Robert M. Merion. (2009) Effect of alcoholic liver disease and hepatitis C infection on waiting list and posttransplant mortality and transplant survival benefit. Hepatology 50:2, 400-406
CrossRef102
Vincent Wai-Sun Wong, Henry Lik-Yuen Chan. (2009) Severe acute exacerbation of chronic hepatitis B: A unique presentation of a common disease. Journal of Gastroenterology and Hepatology 24:7, 1179-1186
CrossRef103
Guadalupe Garcia-Tsao, Joseph Lim. (2009) Management and Treatment of Patients With Cirrhosis and Portal Hypertension: Recommendations From the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. The American Journal of Gastroenterology 104:7, 1802-1829
CrossRef104
Petra Pájer, Imre Fehérvári. (2009) Investigation of renal function in liver transplant patients: MDRD or Cockroft-Gault?. Clinical and Experimental Medical Journal 3:2, 309-317
CrossRef105
Byung Cheol Yun, W Ray Kim. (2009) Editorial: Hyponatremia in Hepatic Encephalopathy:An Accomplice or Innocent Bystander?. The American Journal of Gastroenterology 104:6, 1390-1391
CrossRef106
Andrés Cárdenas, Pere Ginès. (2009) Portal hypertension. Current Opinion in Gastroenterology 25:3, 195-201
CrossRef107
Ashish Upadhyay, Bertrand L. Jaber, Nicolaos E. Madias. (2009) Epidemiology of Hyponatremia. Seminars in Nephrology 29:3, 227-238
CrossRef108
Richard B. Freeman, Neville Jamieson, Douglas E. Schaubel, Robert J. Porte, Federico G. Villamil. (2009) Who should get a liver graft?. Journal of Hepatology 50:4, 664-673
CrossRef109
Didier Samuel. (2009) MELD–Na as a prognostic score for cirrhotic patients: Hyponatremia and ascites are back in the game. Journal of Hepatology 50:4, 836-838
CrossRef110
(2009) Consensus document of the Spanish Society of Liver Transplantation. Waiting lists, liver transplantation, and quality indicators. Cirugía Española (English Edition) 86:6, 331-345
CrossRef111
Petra Pájer, Imre Fehérvári. (2009) A veseműködés vizsgálata májtranszplantált betegeknél: MDRD- vagy Cockroft–Gault-formula?. Orvosi Hetilap 150:4, 155-160
CrossRef112
Noriyo Yamashiki, Yasuhiko Sugawara, Sumihito Tamura, Junichi Kaneko, Kayo Nojiri, Kazuhiko Koike, Norihiro Kokudo. (2009) Referral, evaluation, and listing for deceased donor liver transplantation in Japan: University of Tokyo experience. Kanzo 50:11, 634-643
CrossRef113
(2008) Hyponatremia and Mortality among Patients Waiting for Liver Transplantation. New England Journal of Medicine 359:24, 2615-2615
Full Text114
Cárdenas, Andrés, Ginès, Pere, . (2008) Predicting Mortality in Cirrhosis — Serum Sodium Helps. New England Journal of Medicine 359:10, 1060-1062
Full Text
- Letters
